Reprogramming the course of cancer

Technology

Our platform technologies are designed to administer cancer fighting tumor suppressor genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities.

Pipeline

We are developing our lead product candidate, Oncoprex™ immunogene therapy, to be administered in combination with targeted therapies and immunotherapies for non-small cell lung cancer. Preclinical research indicates that Oncoprex might also be effective in fighting other types of cancer and we are exploring its use in other cancer types.

Management Team

We are a multidisciplinary team with broad business experience in the biotech and pharmaceutical industries, and research and clinical experience at preeminent medical and academic institutions around the world. Our management team pairs an unmatched expertise with a knack for innovation in research.

Learn More

About Us


At Genprex, we are committed to pioneering a new approach to treating cancer, based upon our novel proprietary technology platform, including our initial product candidate, Oncoprex™ immunogene therapy, or Oncoprex. Our platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities.

What they’re saying

In the Media


Catch up with our

Latest News


Genprex Demonstrates Growth and Expansion Through Recent Achievements

Company’s recent performance sets path for future milestones, commercialization

Genprex Manufacturing Partner Aldevron Completes Significant Step in Manufacturing for Oncoprex™ Clinical Development Program

Genprex’s newly manufactured plasmids will be used in clinical trials evaluating Oncoprex™ in combination with targeted therapies and immunotherapies.

Genprex Begins Next Phase of Drug Branding Program

Genprex has initiated the first phase of branding its lead drug candidate and has completed the creation and submission of non-proprietary drug name selections to the American Medical Association’s United States Adopted Names (USAN) Council.

A Potential NSCLC Treatment for Large Patient Populations

Genprex is working on developing its initial drug candidate for NSCLC that would potentially benefit a large patient population who cannot currently benefit from approved therapies.

 
STAY IN THE KNOW WITH
EMAIL NEWS ALERTS
 
Don't miss out. Get our news delivered to your inbox.
 

 
close-link
 
Get Email News Alerts
 
close-link